Recombinant MS4A1 (Ocrelizumab Biosimilar) antibody
This Mammalian Cells Monoclonal antibody specifically detects MS4A1 (Ocrelizumab Biosimilar) in ELISA. It exhibits reactivity toward Human.
Catalog No. ABIN7487883
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 8 Business Days
Quick Overview for Recombinant MS4A1 (Ocrelizumab Biosimilar) antibody (ABIN7487883)
Target
MS4A1 (Ocrelizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This MS4A1 (Ocrelizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb
-
Characteristics
- Antibody Type: IgG1-nd
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- MS4A1 (Ocrelizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission. -
CAS-No
- 637334-45-3
Target
-
You are here:
